Main Pipeline

For Your Healthy Life, NovMetaPharma

Kidney Disease Medication (NovRD)

Pipeline
NovRD
Program Target
Renal Disease
Patient Numbers
697 Million
Development Stage
Research
NovMetaPharma develops NovRD, a chronic kidney disease medication of first-in-class new substance.

The direct medication for chronic kidney disease available is only symptom relief and complication prevention through hypertension medication. Therefore, the market demand for direct chronic kidney disease medication is very high.

NovRD is a first-in-class drug that directly treats chronic kidney disease and has proven its excellent ability to inhibit kidney cell death and inflammation.

Moreover, under the new drug approval process, systematic benefits such as expedited evaluation can be obtained in cases such as chronic kidney disease that are without existing medications.

Accordingly, NovRD’s new drug development and commercialization schedule is expected to be further accelerated and NovMetaPharma is accelerating the development of NovRD currently

01

Inhibition of cell death

Cell death has been confirmed to be effectively inhibited when NovRD was administered.

02

Inhibition of inflammation

Inflammation has been confirmed to be significantly reduced when NovRD was administered.

03

Expedited evaluation

With the high possibility of being designated as Fast Track by the US FDA, the approval of the new drug is expected to proceed quickly

Inhibition of Kidney Cell inflammation
Inhibition of Kidney Cell Death
Inhibition of Kidney Cell Fibrosis
Improve Kidney´s Filtration Function

NovRD Development Status

01

Clinical Development Status
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022

Preclinical

License Out (E)

US clinical phase 1/2a

02

Patent Application and Registration Status
Patents IP Protection
Substance patent (US)
Application
2019
Registration
2020
Patent expiration (expected) year
2039
Cell protection patent (KR-1)
Application
2017
Registration
2019
Patent expiration (expected) year
2037
Cell protection patent (KR-2)
Application
2019
Patent expiration (expected) year
(2037)
Cell protection patent (US)
Application
2019
Patent expiration (expected) year
(2037)
Cell protection patent (EU)
Application
2019
Patent expiration (expected) year
(2037)
Cell protection patent (JP-1)
Application
2019
Registration
2020
Patent expiration (expected) year
2037
Cell protection patent (JP-2)
Application
2019
Patent expiration (expected) year
(2037)
Cell protection patent (CN)
Application
2019
Patent expiration (expected) year
(2037)